Can you elaborate on the specific issues causing delays in the VI integration and what steps are being taken to fully integrate the business?

Jason Weidman clarified that the issues are not product-related but rather integration transitions in three areas: order-to-cash systems, distributor transitions, and sales force realignments. He detailed mitigation efforts for each, expressing confidence that these transient issues will be worked through by year-end. “What it is simply is just integration transitions that are continuing, that are transient that we need to work through. And I would primarily point to 3 areas the first would be order to cash transitions. The second would be distributor transitions and the third would be sales force transitions.”

What is your level of confidence that the current timeline reflects the full extent of the delay for the BIOTRONIK integration?

Jason Weidman stated he has good confidence that the main causes of the integration delay, with mitigation actions already showing progress, should be worked through by the end of the year, and this is reflected in the company's guidance. “I think that when we look at the -- as I said, the main causes of the integration delay we have mitigations in place, and we're already seeing progress in those -- in each of those factors. So we have pretty good confidence or really good confidence that we will -- we should be able to work through that by the end of the year. and thus, our guidance also reflects that.”

Given that some sales roles are still open and ramp-up takes time, how confident are you that the sales force issues will be fully resolved by year-end?

Jason Weidman is confident in the hiring and training plan for the sales force. However, he acknowledged that it typically takes about 6 months for a new rep to get up to speed, implying a gradual ramp-up rather than an immediate resolution by year-end. “I'm confident we can get through the hiring plan. I'm confident with our current reps, we can get through the enhanced training that we need to do. But as you as you know, in these spaces, typically, it takes a good 6 months or so to get a rep up to speed.”

TFX

Teleflex (TFX) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Teleflex Q2 FY26 — Strong Vascular & Surgical Performance Amidst Interventional Integration Challenges

Teleflex delivered better-than-expected Q2 FY26 revenue and EPS, driven by robust performance in its Vascular and Surgical segments. However, the Interventional business faced integration challenges post-acquisition, leading to a revised full-year revenue outlook. The company is actively executing strategic divestitures and capital allocation plans, including significant share repurchases and debt reduction, with management anticipating substantial financial performance improvements in 2027 and beyond.

Highlights

Overall pro forma adjusted constant currency growth was 4.7%.
Adjusted operating margin reached 19.6%.
Adjusted EPS was $1.76, a 1.7% increase year-over-year, exceeding expectations.
Successful close of the OEM divestiture, generating $1.5 billion in proceeds.
FDA BLA approval for EZPlas freeze-dried plasma, expanding the emergency medicine portfolio.

Concerns

Interventional business revenue decreased 1% year-over-year, falling short of expectations due to integration delays.
Adjusted gross margin decreased 280 basis points year-over-year to 61.7%, primarily due to tariffs and the Vascular Intervention business.
Adjusted operating margin decreased 520 basis points to 19.6% due to gross margin pressure, higher operating expenses, and increased R&D.
Full-year 2026 pro forma adjusted constant currency revenue growth guidance lowered to 3.5%-4.5% from 4.5%-5.5%.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 pro forma adjusted constant currency revenue growth	3.5% to 4.5% high materiality	FY26	High
Full-year 2026 adjusted EPS	$6.90 to $7.20 high materiality	FY26	High
Full-year 2026 adjusted operating margin	approximately 19% medium materiality	FY26	High
Steady-state adjusted operating margin	approximately 23% high materiality	Long-term	High
Full-year 2026 net interest expense	approximately $85 million medium materiality	FY26	High
Full-year 2026 adjusted tax rate	approximately 12.25% medium materiality	FY26	High
Full-year 2026 shares outstanding	approximately $43.3 million medium materiality	FY26	High
Annual pretax cost savings from restructuring plan	approximately $50 million medium materiality	Mid-2028 · FY28	High
Financial performance step-up	meaningful step-up high materiality	2027 and beyond · FY27	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Vascular Primarily driven by growth in hemostatic products and the central access portfolio. Management expects a more moderate growth rate in H2 2026 as distributor inventories normalize.	$246.3 million	8%	—	—
Surgical Primarily driven by strong performance in ligation clips, the instrument portfolio, and skin safety. Management expects a more moderate growth rate in H2 2026 due to tougher year-over-year comps.	$112.1 million	9.2%	—	—
Interventional Performance fell short of expectations, impacted by ongoing integration and restructuring activities associated with the VI acquisition. Growth was softer than expected, despite strong performance in several categories like hemostatic products and right heart catheters.	$211.9 million	-1%	—	—

Product announcements

Product	Type	Timeline	Details
EZPlas freeze-dried plasma	launch	late July (BLA approval), 2027 (contributor to revenue)

Deals & partnerships

N/A (buyer not named) Sale of OEM business $1.5 billion (proceeds), $1.25 billion (estimated after-tax proceeds)

Announced in December 2025, successfully closed earlier this week.

N/A (buyer not named) Sale of Acute Care and Interventional Urology businesses

FTC issued a second request in March; both parties are working cooperatively with the FTC. Timing is dependent on the regulatory approval process.

Risks & headwinds

Slower-than-anticipated integration of the Interventional business (VI acquisition) Extended through second half of 2026

Interventional revenue decreased 1% year-over-year; full-year revenue guidance reduced from 4.5%-5.5% to 3.5%-4.5%.

Mitigation:Addressing order-to-cash transitions, distributor transitions, and sales force realignments; implementing enhanced training and a clear hiring plan for the sales force.

Adverse impact of tariffs Q2 FY26

Adjusted gross margin decreased 280 basis points year-over-year.

Mitigation:No specific mitigation mentioned, but the company is not including tariff refunds in its guidance until full confirmation from the U.S. government.

Stranded costs associated with strategic divestitures 2026

Impacts 2026 results.

Mitigation:Multiyear restructuring plan expected to achieve approximately $50 million in annual pretax cost savings by mid-2028; TS and MS agreements for Acute Care and Interventional Urology divestitures are expected to drive adjusted margin expansion in 2027.

What to watch in Q3 FY26

Interventional business integration progress

End of 2026

Current Slower than anticipated, 1% revenue decrease in Q2 FY26.

Target Full integration by year-end 2026.

Why it matters

Successful integration is crucial for improved growth in 2027 and beyond, and for achieving the revised full-year revenue guidance.

Although 2026 was always expected to be a transition year, the integration in the quarter was slower than anticipated, reflecting several transition factors that we expect to be temporary. We are making progress on mitigation actions to address the primary drivers of these temporary impacts. And we remain confident in the long-term strategic and financial prospects for this business.

Find out whether TFX delivers this. Inve re-checks your case every morning.

Q&A highlights

As a new CEO, are there any aspects of the current strategy that make you uncomfortable, and have you identified any new opportunities?

Jason Weidman expressed strong confidence in the transformational strategy, stating it was a key attraction to the role and he sees no reason to deviate. He is currently conducting a comprehensive assessment to develop a long-term operational and strategic plan for sustainable growth and shareholder value.

“I remain confident in that strategy. There is nothing that stuck out to me in these first 2 months that make me think that we're on the wrong path.”

asked by Jayson Bedford · answered by Jason Weidman

2 min read 5 chapters

Detailed narrative

Strategic Transformation & Divestitures Progress

Teleflex is actively pursuing a strategic transformation, including the divestiture of its Acute Care, Interventional Urology, and OEM businesses. The OEM divestiture successfully closed, generating $1.5 billion in proceeds, with an estimated $1.25 billion after-tax. These funds are earmarked for debt reduction and share repurchases.

The remaining divestitures (Acute Care and Interventional Urology) are anticipated to close in Q4 2026, pending FTC regulatory approval, and are expected to further streamline the portfolio and enhance financial flexibility.

Interventional Business Integration Challenges & Mitigation

The integration of the acquired Vascular Intervention (VI) business within the Interventional segment is taking longer than anticipated, leading to a 1% revenue decrease in Q2. Key challenges include order-to-cash transitions causing customer confusion, timing issues with distributor transitions, and sales force realignments requiring enhanced training and new hires.

Management views these as temporary issues and has mitigation plans in place, aiming for full integration by the end of 2026 to position the business for improved growth in 2027 and beyond.

Increased R&D Investment and Innovation Milestones

Teleflex has deliberately increased its R&D investment, with R&D expense reaching 7.9% of sales in the first half of 2026, up from historical levels of 6%. This focus on innovation has yielded significant milestones. The company received FDA BLA approval for EZPlas freeze-dried plasma, a novel solution for emergency medicine.

Additionally, progress continues with the Freesolve drug-eluting resorbable magnesium scaffold, including 4-year follow-up data from BIOMAG-1, completion of patient enrollment in BIOMAG-2, and commencement of the BIOMAG-3 pivotal trial in the U.S.

Disciplined Capital Allocation and Shareholder Returns

The company remains committed to its capital allocation strategy, which includes a $1 billion share repurchase authorization and $800 million in debt reduction. In Q2, Teleflex repurchased 1.9 million shares for $250 million at an average price of $130.85. An additional $250 million accelerated share repurchase is planned, funded by the OEM divestiture proceeds, which also facilitated a $700 million debt repayment.

These actions are expected to contribute to significantly higher adjusted EPS starting in 2027.

2026 as a Transition Year with Future Optimism

Management reiterated that 2026 is a transition year, with results impacted by transient factors related to strategic divestitures and the Interventional business integration. Despite these near-term impacts, the company anticipates 2027 to be more reflective of the underlying business's strength.

They foresee significant improvements in adjusted margins, interest expense, and adjusted EPS, driven by the completion of divestitures, mitigation of stranded costs, and ongoing cost-saving initiatives.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.